Phase 3 trial of dual SGLT inhibitor significantly reduces cardiovascular risk in diabetic patients

On August 23, 2021, Lexicon Pharmaceuticals announced the oral SGLT1/2 dual inhibitor sotagliflozin (trade name Zynquista), the latest in two phase 3 clinical trials for the treatment of patients with type 2 diabetes with worsening heart failure or chronic kidney disease Data analysis

Sotagliflozin simultaneously targets two sodium-glucose cotransporters (SGLT1 and SGLT2) responsible for glucose regulation

In two randomized, double-blind, multi-center, placebo-controlled phase 3 clinical trials, sotagliflozin strongly and significantly reduced heart failure hospitalizations, myocardial infarction, and stroke events in diabetic patients, and was also shown in multiple cardiovascular endpoints Quick and extensive benefits

The SCORED trial evaluated the cardiovascular efficacy of standard treatment + sotagliflozin compared with placebo in 10584 patients with risk of type 2 diabetes, chronic kidney disease, and cardiovascular disease

▲Stagliflozin molecular structure (picture source: User: Edgar181, Public domain, via Wikimedia Commons)

This new analysis evaluated the effects of increasing sotagliflozin from an initial dose of 200 mg and a dose titration to 400 mg in the SOLOIST and SCORED trials against the primary endpoint (composite endpoint of cardiovascular death + hospitalization for heart failure + emergency visits due to heart failure) and other cardiac The impact of renal endpoints

Reference materials:

[1] Lexicon's Sotagliflozin Demonstrates Additional Compelling Benefits in Reducing Cardiovascular Endpoints: Results from Soloist and Scored Trials.

(The original text has been deleted)